Literature DB >> 16893751

Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies.

Stanley S Tai1.   

Abstract

Streptococcus pneumoniae is a causative agent for community acquired pneumonia, bacteremia, acute otitis media, and meningitis. Recent emergence of multi-drug resistant clinical isolates prompts the need of effective vaccine for the prevention of disease. The licensed polysaccharide-based pneumococcal vaccines only elicit protective antibodies against the infection of serotypes that are included in the vaccine. To broaden the protection, the use of pneumococcal proteins will be a feasible and preferable alternative. This communication provides a review on the biochemical properties of these protein candidates, their immunization results in animal studies, and perspectives on the development of protein-based pneumococcal vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893751     DOI: 10.1080/10408410600822942

Source DB:  PubMed          Journal:  Crit Rev Microbiol        ISSN: 1040-841X            Impact factor:   7.624


  60 in total

1.  Pneumococcal vaccination: time to move on?

Authors:  Marijke Johanna Proesmans
Journal:  Eur J Pediatr       Date:  2010-05-15       Impact factor: 3.183

Review 2.  Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets.

Authors:  Lok-To Sham; Ho-Ching T Tsui; Adrian D Land; Skye M Barendt; Malcolm E Winkler
Journal:  Curr Opin Microbiol       Date:  2012-01-24       Impact factor: 7.934

3.  PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  Christina M Croney; Mamie T Coats; Moon H Nahm; David E Briles; Marilyn J Crain
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

4.  Pneumococcal carriage at age 2 months is associated with growth deficits at age 6 months among infants in South India.

Authors:  Christian L Coles; Lakshmi Rahmathullah; Reba Kanungo; Joanne Katz; Debora Sandiford; Sheela Devi; R D Thulasiraj; James M Tielsch
Journal:  J Nutr       Date:  2012-04-25       Impact factor: 4.798

5.  Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.

Authors:  Shifeng Wang; Yuhua Li; Huoying Shi; Giorgio Scarpellini; Ascencion Torres-Escobar; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

6.  Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Jianghong Xu; Wenjia Dai; Zhengmin Wang; Bing Chen; Zhongming Li; Xiaoyong Fan
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

7.  Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.

Authors:  David Verhoeven; Sheldon Perry; Michael E Pichichero
Journal:  Clin Vaccine Immunol       Date:  2014-05-21

8.  Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.

Authors:  Johan Berglund; Peter Vink; Fernanda Tavares Da Silva; Pascal Lestrate; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

9.  Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

Authors:  Adriana T Moreno; Maria Leonor S Oliveira; Daniela M Ferreira; Paulo L Ho; Michelle Darrieux; Luciana C C Leite; Jorge M C Ferreira; Fabiana C Pimenta; Ana Lúcia S S Andrade; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

Review 10.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.